| __timestamp | ACADIA Pharmaceuticals Inc. | CymaBay Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 32748000 | 8185000 |
| Thursday, January 1, 2015 | 90804000 | 8871000 |
| Friday, January 1, 2016 | 186456000 | 9645000 |
| Sunday, January 1, 2017 | 255062000 | 12387000 |
| Monday, January 1, 2018 | 265758000 | 14381000 |
| Tuesday, January 1, 2019 | 325638000 | 19238000 |
| Wednesday, January 1, 2020 | 388661000 | 17425000 |
| Friday, January 1, 2021 | 396028000 | 23040000 |
| Saturday, January 1, 2022 | 369090000 | 25116000 |
| Sunday, January 1, 2023 | 402466000 | 51953000 |
Unleashing the power of data
In the competitive landscape of biotechnology, understanding financial trends is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of CymaBay Therapeutics, Inc. and ACADIA Pharmaceuticals Inc. over the past decade. From 2014 to 2023, ACADIA's SG&A expenses surged by over 1,100%, peaking in 2023. In contrast, CymaBay's expenses grew by approximately 535% during the same period. This stark difference highlights ACADIA's aggressive expansion strategy compared to CymaBay's more conservative approach. Notably, ACADIA's expenses consistently outpaced CymaBay's, reflecting its larger operational scale. The data underscores the importance of strategic financial management in sustaining growth and competitiveness in the biotech sector. As the industry evolves, these trends offer valuable insights into the financial health and strategic priorities of these companies.
Johnson & Johnson vs ACADIA Pharmaceuticals Inc.: SG&A Expense Trends
Comparing SG&A Expenses: AstraZeneca PLC vs CymaBay Therapeutics, Inc. Trends and Insights
BeiGene, Ltd. vs CymaBay Therapeutics, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Blueprint Medicines Corporation vs ACADIA Pharmaceuticals Inc.
Comparing SG&A Expenses: Corcept Therapeutics Incorporated vs ACADIA Pharmaceuticals Inc. Trends and Insights
ADMA Biologics, Inc. or ACADIA Pharmaceuticals Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of ACADIA Pharmaceuticals Inc. and MorphoSys AG
Who Optimizes SG&A Costs Better? ACADIA Pharmaceuticals Inc. or MannKind Corporation
Cost Management Insights: SG&A Expenses for ACADIA Pharmaceuticals Inc. and Geron Corporation
Operational Costs Compared: SG&A Analysis of ACADIA Pharmaceuticals Inc. and BioCryst Pharmaceuticals, Inc.
ACADIA Pharmaceuticals Inc. vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends